Dianthus Therapeutics, Inc. /DE/
Nasdaq · Healthcare · Pharmaceutical Preparations · New York, NY
DNTH chart
What traders are saying about $DNTH
Latest postsDianthus Therapeutics, Inc. /DE/ news
- Dianthus Therapeutics (DNTH) Stock May Look Stretched As Pipeline Progress Draws Focus
Yahoo Finance ·
- Wall Street Analysts See a 61.23% Upside in Dianthus Therapeutics, Inc. (DNTH): Can the Stock Really Move This High?
Yahoo Finance ·
- VANGUARD CAPITAL MANAGEMENT LLC Adds 687,218 Shares of Dianthus
GuruFocus ·
- Dianthus Therapeutics (NASDAQ:DNTH) Stock Price Crosses Above 200-Day Moving Average - Time to Sell?
MarketBeat ·
- Dianthus Therapeutics (DNTH) Stock Forecast and Price Target 2026
MarketBeat ·
- Dianthus Therapeutics, Inc. (DNTH) stock price, news, quote and history
Yahoo Finance UK ·
- Dianthus Therapeutics, Inc. (DNTH) Reports Q3 Loss, Beats Revenue Estimates
Yahoo Finance ·
- Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q3 2026 Financial Results
Yahoo Finance ·
- Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Yahoo Finance ·
- Dianthus Therapeutics to Participate in Five Investor Conferences During November
Yahoo Finance ·
- Regeneron (REGN) Q3 Earnings and Revenues Beat Estimates
Yahoo Finance ·
- Halozyme Therapeutics (HALO) Reports Next Week: Wall Street Expects Earnings Growth
Yahoo Finance ·
Dianthus Therapeutics, Inc. /DE/ key financials
| USD | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Revenue | $2.0M | $6.2M | $2.8M | $6.4M |
| Net income | -$162.3M | -$85.0M | -$43.5M | -$28.5M |
| Diluted EPS | $-4.20 | $-2.55 | $-8.45 | $-32.57 |
| Total assets (year end) | $530.9M | $374.0M | $179.4M | $83.1M |
| Cash and equivalents (year end) | $51.1M | $22.8M | $132.3M | $15.4M |
Calendar-year figures as reported to the SEC in XBRL filings.
Recent SEC filings
About Dianthus Therapeutics, Inc. /DE/
- Ticker
- DNTH (Nasdaq)
- Industry
- Pharmaceutical Preparations
- Headquarters
- New York, NY
- Incorporated in
- DE
- Fiscal year end
- December 31
- SEC CIK
- 1690585
- Former names
- Magenta Therapeutics, Inc.
Frequently asked questions
What exchange is Dianthus Therapeutics, Inc. /DE/ listed on?
Dianthus Therapeutics, Inc. /DE/ trades on the Nasdaq under the ticker symbol DNTH.
What industry is Dianthus Therapeutics, Inc. /DE/ in?
Dianthus Therapeutics, Inc. /DE/ is classified by the SEC under "Pharmaceutical Preparations", part of the Healthcare sector on StockTweeting.
Where is Dianthus Therapeutics, Inc. /DE/ headquartered?
Dianthus Therapeutics, Inc. /DE/'s business address on file with the SEC is in New York, NY.
When does Dianthus Therapeutics, Inc. /DE/'s fiscal year end?
Dianthus Therapeutics, Inc. /DE/'s fiscal year ends on December 31.
How much revenue did Dianthus Therapeutics, Inc. /DE/ report?
Dianthus Therapeutics, Inc. /DE/ reported $2.0M in revenue for calendar year 2025, according to its SEC filings.